CSBio CSBio

X
[{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Treats First Patients in Pivotal JTA-004 Phase III Knee Osteoarthritis Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Bone Therapeutics"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$1.1 million","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics Receives Eur 1.0 Million to Advance Ongoing JTA-004 Phase III Knee Osteoarthritis Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Bone Therapeutics"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Reaches 50% Treated Patients in Ongoing JTA-004 Phase III Pivotal Knee Osteoarthritis Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Bone Therapeutics"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Completes Recruitment and Patient Treatment in JTA-004 Pivotal Phase III Knee Osteoarthritis Study","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Bone Therapeutics"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"European Investment Bank","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics Secures Up to \u20ac16 Million Loan Financing from the European Investment Bank","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Bone Therapeutics"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bone Therapeutics Provides Update on the Progress of Clinical Studies","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Bone Therapeutics"},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSenic Delivers a New Post-Hoc Analysis of Its Phase III JTA-004 trial on Knee Osteo-Arthritis with Positive Action on The Most Severely Affected Patient Population","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"BioSenic"},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSenic Reacquires Global IP Rights and Provides Update On JTA-004 Development","therapeuticArea":"Musculoskeletal","highestDevelopmentStatus":"Phase III","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"BioSenic"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            JTA-004 consists of a unique mix of plasma proteins, hyaluronic acid, a natural component of knee synovial fluid and a fast-acting analgesic. It was designed to provide added lubrication and protection to the arthritic joint cartilage and to alleviate osteoarthritis pain.

            Lead Product(s): Clonidine,Hyaluronic Acid

            Therapeutic Area: Musculoskeletal Product Name: JTA-004

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 17, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            JTA-004 consists of a unique mix of plasma proteins, hyaluronic acid, a natural component of knee synovial fluid and a fast-acting analgesic. It was designed to provide added lubrication and protection to the arthritic joint cartilage and to alleviate osteoarthritis pain.

            Lead Product(s): JTA-004

            Therapeutic Area: Musculoskeletal Product Name: JTA-004

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 16, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The JTA-004 Phase III study is a controlled, randomized, double-blind trial. It is evaluating the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee up to 12 months, compared to placebo or Hylan G-F 20.

            Lead Product(s): JTA-004

            Therapeutic Area: Musculoskeletal Product Name: JTA-004

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 19, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            EIB financing will support and prepare Bone Therapeutics’ lead asset, the enhanced viscosupplement JTA-004, being evaluated in a registrational phase III clinical trial for the treatment of osteoarthritic pain in the knee, for future regulatory approval and commercialization.

            Lead Product(s): Plasma Proteins,Hyaluronic Acid,Fast-acting Analgesic

            Therapeutic Area: Musculoskeletal Product Name: JTA-004

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: European Investment Bank

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Financing July 01, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            JTA-004 is unique patented mix of plasma proteins, hyaluronic acid, and a fast-acting analgesic. Bone Therapeutics has completed recruitment and treated all patients in its pivotal Phase III clinical study with the improved viscosupplement in patients with knee osteoarthritis.

            Lead Product(s): Plasma Proteins,Hyaluronic Acid,Fast-acting Analgesic

            Therapeutic Area: Musculoskeletal Product Name: JTA-004

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 22, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The JTA-004 Phase III study is evaluating the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee compared to placebo or Hylan G-F 20, the leading current osteoarthritis treatment on the market.

            Lead Product(s): Plasma Proteins,Hyaluronic Acid,Fast-acting Analgesic

            Therapeutic Area: Musculoskeletal Product Name: JTA-004

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 20, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Funding will provide further financial support to Bone Therapeutics, in addition to recent financing, to advance its current pivotal phase III clinical study with the enriched protein solution, JTA-004.

            Lead Product(s): Plasma Proteins,Hyaluronic Acid,Fast-acting Analgesic

            Therapeutic Area: Musculoskeletal Product Name: JTA-004

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $1.1 million Upfront Cash: Undisclosed

            Deal Type: Funding August 13, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The JTA-004 phase III study is a controlled, randomized, double-blind trial that will evaluate the potential of a single, intra-articular injection of JTA-004 to reduce osteoarthritic pain in the knee compared to placebo or Hylan G-F 20.

            Lead Product(s): Plasma proteins,Hyaluronic Acid,Fast-acting analgesic

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 18, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY